Long-term Efficacy of Infliximab for Refractory Ulcerative Colitis: Results from a Single Center Experience

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2014 Apr 25

PMID 24758588

Citations 14

Authors

Satoshi Yamada

Takuya Yoshino

Minoru Matsuura

Naoki Minami

Takahiko Toyonaga

Yusuke Honzawa

Yoshihisa Tsuji

Hiroshi Nakase

Affiliations

Soon will be listed here.

Abstract

Background: The long-term efficacy of infliximab (IFX) for patients with refractory ulcerative colitis (UC) is unclear. The aim of this study was to assess the long-term outcomes of IFX treatment in patients with refractory UC.

Methods: Thirty-three patients with refractory UC who received IFX treatment at Kyoto University Hospital between 2003 and 2013 were retrospectively evaluated. IFX intensification was defined as a dose escalation (up to 10 mg/kg) and/or shorter intervals between infusions (every 4-6 weeks).

Results: Of the 33 patients who received scheduled infusions of IFX, 24 (72.7%) achieved clinical remission within 8 weeks after initiating IFX treatment. Of these 24 responders, 17 (70.8%) experienced a relapse of UC and required IFX intensification, and 16 (66.7%) eventually maintained clinical remission with IFX treatment, including IFX intensification. Of the 33 patients, 6 (18.2%) underwent colectomy during IFX treatment. Multivariate regression analysis showed that a serum C-reactive protein (CRP) concentration <5 mg/L two weeks after starting IFX was a predictor of a positive clinical response to IFX induction therapy. No severe adverse events occurred in UC patients treated with IFX.

Conclusion: IFX intensification was necessary for long-term maintenance of remission and to prevent colectomy in patients with refractory UC.

Citing Articles

The Efficacy of Currently Licensed Biologics for Treatment of Ulcerative Colitis: A Literature Review.

Awan H, Fatima U, Eaw R, Knox N, Alrubaiy L Cureus. 2023; 15(4):e37609.

PMID: 37069838 PMC: 10105519. DOI: 10.7759/cureus.37609.

Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis.

Singh H, Wilson L, Tencer T, Kumar J Clinicoecon Outcomes Res. 2023; 15:125-138.

PMID: 36855750 PMC: 9968424. DOI: 10.2147/CEOR.S391413.

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.

Savelkoul E, Thomas P, Derikx L, den Broeder N, Romkens T, Hoentjen F Inflamm Bowel Dis. 2022; 29(10):1633-1647.

PMID: 36318229 PMC: 10547237. DOI: 10.1093/ibd/izac200.

Treatment of Inflammatory Bowel Disease: A Comprehensive Review.

Cai Z, Wang S, Li J Front Med (Lausanne). 2022; 8:765474.

PMID: 34988090 PMC: 8720971. DOI: 10.3389/fmed.2021.765474.

Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates.

Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F Therap Adv Gastroenterol. 2022; 14:17562848211065329.

PMID: 34987611 PMC: 8721421. DOI: 10.1177/17562848211065329.

References

Olsen T, Cui G, Goll R, Husebekk A, Florholmen J . Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2009; 44(6):727-35. DOI: 10.1080/00365520902803507. View

Dave M, Loftus Jr E . Mucosal healing in inflammatory bowel disease-a true paradigm of success?. Gastroenterol Hepatol (N Y). 2012; 8(1):29-38. PMC: 3277196. View

DOvidio V, Vernia P, Gentile G, Capobianchi A, Marcheggiano A, Viscido A . Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol. 2008; 43(2):180-3. DOI: 10.1016/j.jcv.2008.06.002. View

Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A . Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007; 26(5):747-56. DOI: 10.1111/j.1365-2036.2007.03415.x. View

Pillet S, Pozzetto B, Jarlot C, Paul S, Roblin X . Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis. 2012; 44(7):541-8. DOI: 10.1016/j.dld.2012.03.018. View

Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos P, Caprioli F . Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2013; 46(2):135-9. DOI: 10.1016/j.dld.2013.10.007. View

Rutgeerts P, Sandborn W, Feagan B, Reinisch W, Olson A, Johanns J . Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-76. DOI: 10.1056/NEJMoa050516. View

Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P . A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002; 37(7):818-24. View

Moran G, Dubeau M, Kaplan G, Yang H, Seow C, Fedorak R . Phenotypic features of Crohn's disease associated with failure of medical treatment. Clin Gastroenterol Hepatol. 2013; 12(3):434-42.e1. DOI: 10.1016/j.cgh.2013.08.026. View

10.

Yoshino T, Nakase H, Matsuura M, Matsumura K, Honzawa Y, Fukuchi T . Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. Digestion. 2011; 84(1):3-9. DOI: 10.1159/000321911. View

11.

Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M . Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013; 19(5):1065-72. DOI: 10.1097/MIB.0b013e3182802909. View

12.

Rahier J, Ben-Horin S, Chowers Y, Conlon C, De Munter P, DHaens G . European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2010; 3(2):47-91. DOI: 10.1016/j.crohns.2009.02.010. View

13.

Sutherland L, Martin F, Bailey R, Fedorak R, Poleski M, Dallaire C . A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology. 1997; 112(4):1069-77. DOI: 10.1016/s0016-5085(97)70117-3. View

14.

Seow C, Newman A, Irwin S, Steinhart A, Silverberg M, Greenberg G . Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2009; 59(1):49-54. DOI: 10.1136/gut.2009.183095. View

15.

Panaccione R, Ghosh S, Middleton S, Marquez J, Scott B, Flint L . Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014; 146(2):392-400.e3. DOI: 10.1053/j.gastro.2013.10.052. View

16.

Lewis J . The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011; 140(6):1817-1826.e2. PMC: 3749298. DOI: 10.1053/j.gastro.2010.11.058. View

17.

Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G . Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2010; 2(3):219-25. DOI: 10.1016/j.crohns.2008.03.004. View

18.

Kane S, Sandborn W, Rufo P, Zholudev A, Boone J, Lyerly D . Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003; 98(6):1309-14. DOI: 10.1111/j.1572-0241.2003.07458.x. View

19.

Knight D, Trinh H, Le J, Siegel S, Shealy D, McDonough M . Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993; 30(16):1443-53. DOI: 10.1016/0161-5890(93)90106-l. View

20.

Matsumura K, Nakase H, Kosugi I, Honzawa Y, Yoshino T, Matsuura M . Establishment of a novel mouse model of ulcerative colitis with concomitant cytomegalovirus infection: in vivo identification of cytomegalovirus persistent infected cells. Inflamm Bowel Dis. 2013; 19(9):1951-63. DOI: 10.1097/MIB.0b013e318293c5bf. View